Consolidated Statements of Operations - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues		$ 314,393	$ 262,741	$ 889,840	$ 765,126
Cost of goods sold		253,515	210,549	712,573	611,394
Gross profit		60,878	52,192	177,267	153,732
Selling, general, and administrative expenses		165,491	58,522	256,942	128,310
Operating income (loss)		(104,613)	(6,330)	(79,675)	25,422
Other expenses:
Interest expense		1,026	716	2,857	2,120
Other expense (income), net		2	(51)	166	141
Total other expenses		1,028	665	3,023	2,261
Income (loss) before income taxes		(105,641)	(6,995)	(82,698)	23,161
Provision for income taxes		176		176
Net income (loss)		(105,817)	(6,995)	(82,874)	23,161
Less net income (loss) attributable to Guardian Pharmacy, LLC prior to the Corporate Reorganization		9,350	(11,290)	22,760	11,884
Less net income attributable to non-controlling interests		6,823	$ 4,295	16,356	$ 11,277
Net income (loss) attributable to Guardian Pharmacy Services, Inc.		$ (121,990)		$ (121,990)
Class A and Class B common stock [Member]
Net income (loss) per share of Class A and Class B common stock
Basic	[1]	$ (2)		$ (2)
Diluted	[1]	$ (2)		$ (2)
Weighted-average Class A and Class B common shares outstanding
Basic		61,143,311		61,143,311
Diluted		61,143,311		61,143,311

[1] Basic and diluted net income (loss) per share of Class A and Class B common stock is applicable only for the period from September 27, 2024 through September 30, 2024, which is the period following the initial public offering (“IPO”) and related Corporate Reorganization (as defined in Note 1 to the Unaudited Interim Consolidated Financial Statements). See Note 7 for the number of shares used in the computation of net income (loss) per share of Class A and Class B common stock and the basis for the computation of net income (loss) per share.